| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 572,3 k € | +33.0% | 430,3 k € | -9.9% | 477,9 k € | +7.2% | 445,7 k € | +67.9% | 265,4 k € | -24.6% | 352,2 k € | +55.7% | 226,1 k € | +592.0% | 32,7 k € | +2119.8% | 1,5 k € | +103.7% | -39,3 k € | +33.6% | -59,2 k € | |
| EBITDA | 254,3 k € | +39.1% | 182,8 k € | -34.4% | 278,7 k € | +18.4% | 235,4 k € | +161.2% | 90,1 k € | -62.9% | 242,8 k € | +82.3% | 133,2 k € | +532.2% | -30,8 k € | +39.6% | -51,0 k € | +45.0% | -92,8 k € | -23.2% | -75,3 k € | |
| Operating profit | 141,4 k € | +65.9% | 85,2 k € | -55.4% | 191,1 k € | +27.9% | 149,4 k € | +9229.6% | 1,6 k € | -98.9% | 150,1 k € | +248.3% | 43,1 k € | +135.7% | -120,6 k € | -2.7% | -117,4 k € | +18.6% | -144,2 k € | -14.2% | -126,3 k € | |
| Profit/loss | 91,8 k € | +63.1% | 56,3 k € | -68.0% | 175,8 k € | +35.5% | 129,8 k € | +2300.6% | -5,9 k € | -104.2% | 139,7 k € | +359.7% | 30,4 k € | +124.0% | -126,6 k € | -6.5% | -118,8 k € | +18.9% | -146,6 k € | -15.7% | -126,7 k € | |
| Equity | 933,6 k € | +10.9% | 841,8 k € | +7.2% | 785,5 k € | +28.8% | 609,7 k € | +27.0% | 479,9 k € | +96.2% | 244,6 k € | +141.1% | -595,1 k € | -31.2% | -453,7 k € | -38.7% | -327,1 k € | -57.1% | -208,3 k € | -237.8% | -61,7 k € | |
| Total assets | 1,5 M € | -1.7% | 1,6 M € | +1.3% | 1,5 M € | -2.9% | 1,6 M € | +2.3% | 1,5 M € | +16.6% | 1,3 M € | +7.2% | 1,2 M € | +17.0% | 1,1 M € | +100.3% | 526,2 k € | +35.7% | 387,7 k € | -6.8% | 416,1 k € | |
| Cash | 182,8 k € | -20.9% | 231,0 k € | +533.4% | 36,5 k € | -79.1% | 174,5 k € | -0.1% | 174,7 k € | +192.0% | 59,8 k € | +206.8% | 19,5 k € | -60.4% | 49,3 k € | +59.8% | 30,8 k € | +70.2% | 18,1 k € | -52.2% | 37,9 k € | |
| Debts | 590,8 k € | -16.7% | 708,8 k € | -4.9% | 745,2 k € | -22.9% | 966,8 k € | -8.9% | 1,1 M € | +2.2% | 1,0 M € | -41.9% | 1,8 M € | +18.7% | 1,5 M € | +78.3% | 844,2 k € | +42.4% | 592,6 k € | +24.9% | 474,4 k € | |
| Staff | 2,3 | — | — | — | — | — | — | 4,2 | 1,6 | 1,9 | 1,5 | |||||||||||
Public limited company · Ath · incorporated on 25/02/2011 · 2,3 ETP
Public limited company profitable and well capitalised. Cash position declining (-20.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
CEREPHARMA is a Public limited company incorporated in 2011. Its main activity is: Manufacture of perfumes and toilet preparations. Its registered office is in Ath. It employs on average 2,3 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette